** Shares of screening services provider HRT.N up 21.6% at
$15.26 - set for their best session
** Co on Monday forecast FY22 revenue between $805 mln and
$820 mln, compared with analysts' estimates of $769 mln
urn:newsml:reuters.com:*:nBw78gp1Va
** Also reported a 32.3% rise in Q4 revenue to $198.5 mln,
beating expectations
** But at least 3 brokerages cut PT on stock, with Stifel
lowering it to $18.5 from $21 and Truist trimming it by $3 to
$17
** "We believe industry competition, ongoing need for tech
investment and normalizing structural screening demand will
limit multiple expansion" - Truist
** Avg. rating of 10 analysts is "buy"; median PT is $21.50
- Refinitiv data
** Stock had fallen ~4% YTD
(Reporting by Tiyashi Datta in Bengaluru)
((tiyashi.datta@thomsonreuters.com))